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Cancer Cell
Previewsprovide a tool to better understand the
pathogenesis of LGL and other MPNs re-
ported to be reliant on STAT5 signaling,
such as polycythemia vera, essential
thrombocythemia, and myelofibrosis.
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The complex tumor microenvironment can make molecularly subtyping cancer using mRNA expression
challenging, particularly for cancers with low epithelial content, such as pancreatic cancer. In a recent edition
of Nature Genetics, Moffitt and colleagues show that subtracting normal epithelial transcripts can provide
insights into the molecular pathology of pancreatic cancer.Pancreatic ductal adenocarcinoma
(PDAC) continues to be the fourth leading
cause of cancer death in our society, with
little if any improvement in outcomes for
over 40 years. Systemic therapies offer
only incremental overall survival advan-
tages but can be associated with signifi-
cant responses in subgroups of patients
that cannot be predicted prior to treat-
ment. As a consequence, there is an
urgent need to better define subgroups
of patients that derive benefit from current
treatment and identify novel therapeutic
strategies. Recent large-scale cancer
genomic studies demonstrate a heteroge-
neous mutational profile, with activating
mutations of KRAS present in over
90%, mutations of TP53, CDKN2A, and
SMAD4 in over 50% of cases among asea of diverse infrequently mutated genes
mostly at a prevalence of less than 5%
(Biankin et al., 2012; Waddell et al.,
2015; Witkiewicz et al., 2015). Although
some studies report potential prognostic
and predictive genomic markers, few
have been validated and none are used
in the clinic. A recent issue of Nature
Genetics presented an article by Moffitt
et al. (2015), who assessed aberrant
gene expression in pancreatic cancer
to define molecular subtypes of tumor
epithelium and stroma, with some fea-
tures associated with patient outcome.
Expression profiling has defined sub-
types in many cancer types, including
breast and ovarian cancer, often with
clinical relevance and usually the result
of many studies that validated and refinedinitial findings. The density of mRNA
expression information overcomes the
relative diversity and sparseness of
genomic mutation data to allow the
modeling of differential expression relative
to clinico-pathological attributes. A char-
acteristic feature of PDAC is the abundant
stroma, which, on average, constitutes
over 70% of the tumor mass. In addition,
PDAC’s infiltrative nature means that
the tumor can include normal pancreas
(containing exocrine epithelium that se-
cretes digestive enzymes and endocrine
cells that secrete digestive hormones,
including insulin and glucagon as well as
a variety of others). These factors have
made defining molecular subgroups and
identifying carcinogenic mechanisms
based on mRNA expression challenging., October 12, 2015 ª2015 Elsevier Inc. 411
Cancer Cell
PreviewsUsing mathematical approaches, Mof-
fitt et al. (2015) subtracted the potential
confounding effects of normal pancreas,
allowing them to uncover candidate
carcinogenic mechanisms of importance,
particularly in the microenvironment.
Our increasing appreciation of the tumor
microenvironment in cancer has led to
novel therapeutic strategies targeting the
immune system. Although these immuno-
therapeutic strategies are showing pro-
mising results in melanoma and colon
cancer, results in PDAC have, thus far,
been disappointing. Moffitt et al. (2015)
provide compelling evidence that the
pancreatic cancer microenvironment
differs substantially between tumors,
heralding the likely necessity of patient
selection based on molecular subtyping
of the microenvironment in order to
adequately assess immune and other
therapies targeting related mechanisms
in the clinic. They defined two subtypes
of stroma, which they termed ‘‘normal’’
and ‘‘activated’’. While a number of genes
differentiated the two subtypes, high
expression of genes associated with
macrophages were a distinct component
of activated stroma. This dichotomy in
stromal expression patterns might also
explain the conflicting results that have
been attributed to the PDAC stroma in
the last few years, vis-a`-vis its role in tu-
mor progression (Gore and Korc, 2014),
and is likely to inform how stroma-tar-
geted therapies are applied in the clinic.
Previously, Collisson et al. (2011)
physically microdissected neoplastic
epithelium from PDAC and performed
array-based transcript profiling. They
uncovered three groups, which they
termed ‘‘classical,’’ ‘‘quasimesenchymal’’
and ‘‘exocrine-like’’ based on unsuper-
vised clustering approaches. In contrast,
Moffitt et al. (2015) defined only two sub-
groups, which they termed ‘‘classical’’
and ‘‘basal,’’ the former being equivalent
to Collisson’s classical subtype and the
latter overlapping with, but not exclu-
sively, quasimesenchymal. Although
subtracting transcripts associated with
normal pancreas facilitated defining carci-
nogenic mechanisms, it was based on the
assumption that cancers do not express
mRNA that is present in the differentiated
normal epithelium of that organ. Any
‘‘exocrine-like’’ subtype would be driven
in part by transcripts defining differenti-
ated exocrine pancreas and would not412 Cancer Cell 28, October 12, 2015 ª2015be apparent if these were removed as
per the Moffitt et al. (2015) algorithm.
Formany years, pathologists have used
the expression of genes to classify can-
cers based on their organ-of-origin or
the putative cell-of-origin within that
organ. For example, a subset of neuro-
endocrine tumors of the pancreas ex-
presses insulin, glucagon, or pancreatic
polypeptide, which are also expressed
by corresponding non-neoplastic islets
(deWilde et al., 2012). Comparable exam-
ples abound, such as the expression
of Clara cell markers in pulmonary adeno-
carcinomas or glial fibrillary acidic protein
(GFAP) in tumors of glial origin. In the
clinic, carcinomas of unknown primary
(CUP) are designated an organ-of-origin
based on the expression of genes
involved in the development or the differ-
entiated state of that organ (Varadhach-
ary, 2013). In the context of exocrine neo-
plasms of the pancreas, themost extreme
example pertains to so-called acinar cell
carcinomas, whose diagnostic sine qua
non is expression of digestive enzymes
native to non-neoplastic acinar cells,
such as lipase or chymotrypsin. Studies
conducted in genetically engineered
mouse models (GEMMs) of pancreatic
cancer strongly suggest that acinar
cells are the most likely cells of origin for
PDAC (Habbe et al., 2008; Kopp et al.,
2012). These acinar cells undergo a
process of acinar-to-ductal metaplasia,
which are clearly evident in GEMMs, and
while human PDAC do not overtly express
markers of terminal acinar differentiation,
it follows that these tumors are likely to
retain such transcriptional networks at
least early in their molecular evolution.
From an ontogeny perspective, the ex-
pression of PDX1, a transcription factor
that assigns pancreatic cell fate in the
midgut, is shared between all pancreatic
neoplasms in variable proportions (Park
et al., 2011), confirming the persistence
of tissue-specific transcriptional pro-
grams in neoplasms of otherwise distinct
histology. Nonetheless, while making
assumptions concerning the expression
of transcripts native to the differentiated
state of the organ may hamper the resolu-
tion of a holistic classification, Moffitt
et al. (2015) elegantly demonstrate that
meaningful data concerning pancreatic
carcinogenesis can be uncovered.
Further studies are urgently needed that
overcome some of the technical chal-Elsevier Inc.lenges of analyzing genomic and tran-
scriptomic data in tumors with highly
variable and sometimes extremely low
epithelial contents. Understanding the
tumor as a whole, the epithelium and
its microenvironment, and the complex
biochemical processes and molecular
mechanisms at play holds significant
promise in advancing cancer therapeutics
in the future.
An important element that has yet to
be addressed is the clonal evolution of
a tumor and the intra-tumoral heteroge-
neity that is manifest, particularly with
respect to gene expression. Although
we are beginning to understand clonal
evolution in cancer based on mutations,
we do not have meaningful data con-
cerning differences in transcript, or pro-
tein, expression within a tumor. Limited
studies in synchronous primary and me-
tastases obtained from terminal PDAC
patients suggest that the degree of het-
erogeneity in the actionable ‘‘proteome’’
is likely to be profound. It is conceivable
that each tumor contains all particular
subtypes with areas of active and inactive
(normal) stroma, foci of inflammation,
and variable epithelial cellularity. Eluci-
dating how these levels of heterogeneity
impact response to therapy is likely
to be the next chapter in our evolving
understanding of the PDAC molecular
landscape.
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